CTT Pharmaceutical CEO acquires shares worth $4,107

Published 09/06/2025, 16:58
CTT Pharmaceutical CEO acquires shares worth $4,107

In a recent filing, CTT Pharmaceutical (TADAWUL:2070) Holdings, Inc. (OTC:CTTH) reported that its CEO, Ryan Khouri, acquired a significant number of shares. On June 9, 2025, Khouri purchased 82,158 shares of the company at $0.05 per share, totaling $4,107. This transaction increased his direct ownership to 6,832,558 shares. The purchase price represents a premium to the current trading price of $0.03, with the stock trading near its 52-week low of $0.02 and significantly below its high of $0.15.

Additionally, on April 11, 2025, Khouri acquired 150,000 shares at $0.06 per share, amounting to $9,000. These acquisitions reflect Khouri’s continued investment in the company, aligning his interests with those of the shareholders. With a market capitalization of just $1.49 million and a weak financial health score, InvestingPro analysis reveals 11 additional key insights about CTTH’s investment potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.